YOUR PARTNERS
IN THE QUEST FOR
BETTER HEALTHCARE


Myriad Life Sciences is a strategic advisory and venture accelerator in the life sciences industry,
partnering with pioneers in the bio-pharmaceutical industry to accelerate the delivery of innovations and medical breakthroughs

Contact Us

WHAT WE DO

We combine global expertise and local insights to address the most complex issues that today's healthcare companies face,
and scout the globe for therapeutic opportunities those which an infusion of capital and strategic guidance will greatly enhance chances of success

Strategic Advisory

  • 01

    Valuation and Deal Advisory

    Asset valuation, deal structuring and investment feasibility analysis

  • 02

    IPO Advisory

    Technical evaluation process support, IPO corporate valuation

  • 03

    Business Development Advisory

    Partnership development, alliance management and transaction execution

Venture Accelerator

  • 01

    NewCo Creation

    We pave the road from scouting therapeutic breakthrough to building the right team,
    to cultivate today’s most promising bio ventures

  • 02

    Growth Acceleration

    We run tailored programs to navigate our portfolios accelerate through
    key R&D and business milestones and value inflection points

  • 03

    Capital Investment and Fundraising

    We invest seed and growth capital, manage a series of venture funds,
    and lead fundraising campaigns to ensure sustainable growth

OUR PEOPLE

Our cross-functional team of R&D,
Business Development, Corporate Strategy and
Venture Investment bring a balance of expertise
that ensure our partners get ahead of the curve

Brian Sung

Chief Executive Officer

Sunghoon Byun

Executive Vice President

Doohong Park

Ph.D. / Chief Technology Officer

Mina Lee

Managing Director

Hyungkoo Chung

Director

Hyungsog Hwang

Chief Financial Officer

Yohan Kim

Manager

John Wonjoon Cho

Manager

Seongun Kim

Manager

Advisory Board

Ph.D.
Youngwhan Park

  • CEO at Avelos Therapeutics

  • (Previous) National OncoVenture, Daewoong, Merck

Ph.D.
Soongyu Choi

  • CTO at Avelos Therapeutics

  • (Previous) YUHAN, GC Pharma, PTC Therapeutics, Bayer Healthcare

Ph.D.
Sungsook Lee

  • Consultant

  • (Previous) National OncoVenture, Chong Kun Dang, CEREP

Ph.D.
Youngwoo Park

  • CEO at YBiologics

  • (Previous) KRIBB, LG Life Sciences

Ph.D.
Byoungchul Lee

  • CEO at Kanaph Therapeutics

  • (Previous) Santen, 23andMe, Genentech

M.D., Ph.D.
Wooick Jang

  • Senior Advisor at CHA Advanced Research Institute

  • (Previous) SL Bigen, Lilly, MSD, Handok

M.D., Ph.D.
Woochan Son

  • Professor at Asan Medical Center, Department of Pathology

  • (Previous) Huntingdon Life Sciences, Medizinische Hochschule Hannover, LG Chem

Ph.D.
Younggeun Shin

  • Professor at Chungnam National University

  • (Previous) Genentech, GSK

Ph.D.
Youngjoon Park

  • CEO at IMDpharm & Professor at Ajou University

  • (Previous) YUHAN, Samil Pharm, CJ Healthcare

 
Jungkue Lee

  • CEO at Bridge Biotherapeutics & Advisor at 3billion

  • (Previous) OliPass, Rex Bio, GalPharma, Crystal Genomics, LG Chem

 
Seungtaek Kwon

  • Managing Director, Hana Financial Investment

 
Jangsub Lee

  • Senior General Manager, Hana Financial Investment

  • (Previous) ILJIN Group

 
Danil Lee

  • Managing Director, Mirae Asset Securities

Attorney
Dongkwan Kwon

  • Head Attorney at Myriad Intellectual Property

  • (Previous) LG Display, Homeplus

Patent Attorney
Jeonghyun Kim

  • Head Patent Attorney at IPscent

  • (Previous) KOREANA Patent firm, ORIGIN Patent & Law firm

OUR EXPERIENCES

01

Strategic Advisory

We have advised leading biotechs and pharmaceuticals assess commercial value of their portfolio,
pass through the KOSDAQ IPO processes, and explore global partnering opportunities

Valuation and Deal Advisory

IPO Advisory

Business Development Advisory

02

Venture Accelerator

Avelos Therapeutics

Avelos Therapeutics was founded in September 2021, where Myriad led creation of the company and
invested seed capital upon establishment. Avelos is committed to the design and development of
small molecule therapeutics for Oncology. Avelos is advancing therapeutic targets that are potentially
first-in-class or best-in-class, with strategic focus on synthetic lethality, cell cycle regulation and
undruggable targets


NIO BioPharm

NIO BioPharm was founded in April 2021, where Myriad participated as angel investor.
NIO BioPharm owns three proprietary platform technologies to identify next generation immune
checkpoints targets, discover novel antibodies, and develop antibodies for ADC applications.
As part of Myriad’s accelerator program, Nio BioPharm is focusing on development of novel,
first-in-class therapeutic antibody and bi-specifics in the immuno-oncology space

CONTACT

GET IN TOUCH

To learn more about Myriad Life Sciences, or to discuss a potential partnership,
or investment opportunity, please contact:

  • Name
  • Company
  • Phone
  • Email
  • Title
  • Content

Address

Myriad Bldg., 67-11, Nonhyeon-ro 149-gil, Gangnam-gu, Seoul,
06039, of Korea

Phone number

+82 2-2138-6130